**BC2 CTSI Annual Meeting Poster Abstract (<450 words)**

In order to best serve their members, and to help eliminate redundancies among the various entities that currently collect samples, the IU Simon Comprehensive Cancer Center (IUSCCC) has combined some of their biobanking efforts. The resulting new **B**iospecimen **C**ollection and **B**iobanking **C**ore – or BC² – has merged the IUSCCC Tissue Procurement Core (TPC), the Komen Tissue Bank (KTB), the Oncology Research Information Exchange Network (ORIEN), and the biobanking efforts of the Clinical Trials Office (CTO). BC² provides staff with cross-training, a more equitable distribution of work, and an opportunity for professional growth. The new core also provides the separate groups with future stability through additional integration into the IUSCCC. This poster presents the important factors of each separate repository and describes how they can be stronger together.

The TPC collects samples in the OR from patients undergoing cancer surgeries. The group is supported by technicians and a consenter and provides samples mostly to IU researchers. Some samples are collected all the time and kept in storage, others are gathered as the result of researcher request.

The KTB is the only known biorepository in the world that collects healthy breast tissue and whole blood from volunteer women with no sign of breast cancer. The KTB, which was formalized in 2007 through funding from the Susan G. Komen Foundation, is fully part of Indiana University, and places great focus on increasing the availability of samples from Black and Brown women. The KTB collects fresh frozen tissue, formalin-fixed paraffin-embedded (FFPE) tissue; blood products including whole blood, plasma, serum, and DNA from lymphocytes.

In 2018, IUSCCC joined ORIEN, a consortium of 18 NCI Designated Cancer Centers, IUSCCC. Through this action, the IUSCCC gained the ability to share data and specimens across the institutions, made possible through the use of a common protocol, the Total Cancer Care (TCC) Protocol. The TCC Protocol allows for the collection of prospective and retrospective biospecimens and clinical data across the lifespan of participants. Select participants have genomic sequencing. The IUSCCC TCC Team helps facilitate investigator use of the data and specimens that are generated through the TCC Protocol both locally and nationally, depending on the investigator’s needs.

The CTO biospecimen lab techs support the IU CTO by assembling “kits” of required/requested samples tailored for each individual cancer study the CTO supports. These kits are prepared and delivered to the study coordinator, who then disseminates them to the appropriate research teams.

By joining forces in collaboration, the four components of BC2 are now working together as one to help the IUSCCC deliver leading-edge care options and the latest advances in cancer research to its patients.